Be Alert for Rare Risks with Janus Kinase Inhibitors (Xeljanz, Etc)

April 2021

Risks with tofacitinib (Xeljanz, Xeljanz XR) are stacking up.

Xeljanz already has a boxed warning about serious infections...malignancy...thrombosis...and mortality.

Now FDA is alerting about more evidence that Xeljanz is associated with cancer (lung, etc)...and CV events (MI, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

COVID-19 Address New Questions About COVID-19 Vaccines
Headache Monitor BP in Patients on Injectable CGRP Antagonists (Aimovig, Etc)
COVID-19 Identify Candidates for COVID-19 Monoclonal Antibodies
COVID-19 Put Inhaled and Oral COVID-19 Treatments in Perspective
Liver Disease Manage Dose Adjustments in Liver Disease
Immunosuppressives Be Alert for Rare Risks with Janus Kinase Inhibitors (Xeljanz, Etc)
Bowel Preps Know the Ins and Outs of Bowel Preps
Diabetes Ensure Eligible Patients With Diabetes Are on a Statin
Heart Failure Think of Verquvo as a “Niche” Med for Heart Failure
Venous Thromboembolism Guide Safe Use of Alteplase for Catheter-Directed Thrombolysis
New Drugs Assess the Role of Remimazolam for Procedural Sedation
Cardiology Know the Latest About Antithrombotics in Heart Valve Replacement